Endpoints News

Endpoints News

RevMed drug's list price is $39,800 a month		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M T W Thu F

27 August, 2026

One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.

news

Generate:Biomedicines discloses early respiratory drug data after congress poster leak

FDA approves Revolution Medicines' pancreatic cancer drug, ushering in new era of KRAS therapy

Biohaven strikes $795M deal for commercial partner in epilepsy

Aug 27

12:00 pm ET

Same molecule, different paths: Where value goes in cross-border dealmaking in a new era

sponsored by PharmCube

Sep 03

11:00 am ET

How leading pharma organizations are putting AI agents to work

sponsored by Medable

Sep 10

11:00 am ET

Inside the IDMO model: Analytical comparability, regulatory readiness and operational excellence

sponsored by Cellares

Sep 16

2:00 pm ET

Beyond ICD codes: Unlocking rare disease insights with genomics and claims-based data

sponsored by GeneDx

Sep 22

12:00 pm ET

The future of drug pricing: Medicare negotiation, MFN models & beyond

sponsored by ADVI

Twenty new honorees join the 140-plus women Endpoints News has recognized for reshaping biopharma. How did they get there, and what's changed? Join us for exclusive interviews, in-depth profiles and a frank look at gender representation in the industry today. Register now.

ENDPOINTS PHARMA

MassBio CEO calls 2025 ‘probably the most challenging year that I can remember’

Cellares rebukes Bristol Myers' criticism of its cell therapy technology

Akeso, Summit hail ivonescimab's biliary tract cancer win in China-only Phase 3 trial

in case you missed it

1.

An uncertain future for Aurora, the first startup dedicated to custom CRISPR therapies

2.

News Briefing

Haisco grants license to Sentivera; ViiV's HIV treatment OK'd for newborns

3.

Spyre drops rheumatoid arthritis hopes for anti-TL1A drug after modest Phase 2 data

4.

Exclusive: Can AI chop clinical trial timelines in half? Faro raises $37M to find out

5.

Americans encounter risks at psychedelic clinics abroad

6.

Boston Scientific hit by cyberattack, global operations affected

Reynald Castaneda

.

Revolution Medicines' closely watched pancreatic cancer drug got its F